Objective  Systematic evaluation of the efficacy and safety of the Rituximab plus gemcitabine and oxaliplatin(R-GemOx) regimen for the treatment of relapsed refractory B-cell lymphoma.

Methods  The PubMed, Embase, CNKI, CBM, VIP and Wan-Fang databases were systematically searched for experimental and observational studies on the R-GemOx regimen for relapsed refractory B-cell lymphoma. The search time frame is from the establishment of each database to September 13, 2022. After extracting the literature and evaluating the quality of the literature in parallel, Meta-analysis was performed using R(4.2.1) software.

Results  A total of 526 cases of relapsed refractory B-cell lymphoma were included in 13 studies. Meta-analysis showed that the complete response rate(CRR) was 37.48% [95%CI(30.25%, 46.45%)] ; partial response rate(PRR) was 28.62% [95%CI(21.06%, 38.90%)]; stable disease rate(SDR) was 12.03% [95%CI(7.03%, 17.93%)] ; progressive disease rate(PDR) was 21.20% [95%CI(15.73%, 27.22%)]; over response rate(ORR) was 62.19% [95%CI(52.25%, 74.02%)] ; clinical benefit rate(CBR) was 79.40% [95%CI(72.49%, 85.62%)]. Safety was dominated by hematological system toxicity, digestive system toxicity and nervous system toxicity.

Conclusion  The R-GemOx regimen for relapsed refractory B-cell lymphoma is an effective treatment option with tolerable drug toxicity.

1.中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(7): 707-735. [Lymphoma Committee of China Anti-Cancer Association, The Society of Oncology of Chinese Medical Doctor Association, Chinese Society for the Promotion of International Exchanges in Health Care Oncology Medical Branch. Clinical practice guideline for lympoma in China (2021 Edition)[J]. Chinese Journal of Oncology, 2021, 43(7): 707-735.] DOI: 10.3760/cma.j.cn112152-20210516-00382.

2.肖慧, 吴凡, 安福润, 等. 1990—2019年中国非霍奇金淋巴瘤疾病负担分析. 中国循证医学杂志, 2023, 23(8): 880-886. [Xiao H, Wu F, An FR, et al. Disease burden analysis of non-Hodgkin lymphoma in China from 1990 to 2019[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(8): 880-886.] DOI: 10.7507/1672-2531.202303171.

3.Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.

4.中华人民共和国国家卫生健康委员会. 淋巴瘤诊疗指南(2022 年版)[EB/OL].（2022-04-19）[2022-12-01]. http://www.nhc.gov.cn/yzygj/s7659/202204/a0e67177df1f439898683e1333957c74/files/abcfc8aae54a4c3bbcfc5c6eea87cb71.pdf

5.Adami HO, Hunter DJ,  Lagiou P. Textbook of cancer epidemiology(1st edn)[M]. New York: Oxford University Press, 2008.

6.Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068. DOI: 10.1200/JCO.2013.54.8800.

7.曾宪涛, 包翠萍, 曹世义, 等. Meta分析系列之三: 随机对照试验的质量评价工具[J]. 中国循证心血管医学杂志, 2012, 4(3): 183-185. [Zeng XT, Bao CP, Cao SY, et al. Quality assessment tools for randomized controlled trial: meta analysis Ⅲ[J]. Chinese Journal of Evidence-Bases Cardiovascular Medicine, 2012, 4(3): 183-185.] DOI: 10.3969/j.issn.1674-4055.2012.03.003.

8.Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument[J]. ANZ J Surg, 2003, 73(9): 712-716. DOI: 10.1046/j.1445-2197.2003.02748.x.

9.López A, Gutiérrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study[J]. Eur J Haematol, 2008, 80(2): 127-132. DOI: 10.1111/j.1600-0609.2007.00996.x.

10.Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (RGemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation[J]. Leuk Lymphoma, 2021, 62(9): 2161-2168. DOI: 10.1080/10428194.2021.1901090.

11.Dhanapal V, Gunasekara M, Lianwea C, et al. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab: a retrospective, multicentre study[J]. Leuk Lymphoma, 2017, 58(9): 1-9. DOI: 10.1080/10428194.2016.1276288.

12.张呈, 苏铭俊, 容庭杰, 等. R-GEMOX方案治疗复发难治B细胞性非霍奇金淋巴瘤的疗效[J]. 现代肿瘤医学, 2018, 26(24): 4008-4010. [Zhang C, Su MJ, Rong TJ, et al. Efficacy of R-GEMOX regimen in the treatment of relapsed/refractor B-cell non-Hodgkin's lymphoma[J]. Journal of Modern Oncology, 2018, 26(24): 4008-4010.]DOI: 10.3969/j.issn.1672-4992.2018.24.030.

13.王汉姣, 曹爱玲. R-GEMOX方案补救治疗复发或难治性弥漫大B细胞淋巴瘤[J]. 现代肿瘤医学, 2012, 20(11): 2376-2378. [Wang HJ, Cao AL. Salvage therapy with rituximab,gemcitabine and oxaliplatin (R-GEMOX) for relapsed or refractory diffuse large B-cell lymphoma[J].  Journal of Modern Oncology, 2012, 20(11): 2376-2378.]DOI: 10.3969/j.issn.1672-4992.2012.11.54.

14.赵蓉爽, 张明智. R-GemOx方案和R-GDP方案二线治疗复发难治性弥漫大B细胞淋巴瘤的临床比较观察[J]. 肿瘤基础与临床, 2021, 34(3): 203-207. [Zhao RS, Zhang MZ. Clinical comparative study of R-GemOx regimenand R-GDP regimenas second-line regimens for patients with relapsed or refractory diffuse large B-cell lymphoma[J]. Journal of Basic and Clinical Oncology, 2021, 34(3): 203-207.] DOI: 10.3969/j.issn.1673-5412.2021.03.005.

15.张会来, 王华庆, 付凯, 等. R-GemOx与RICE方案二线治疗复发或难治性弥漫大B细胞淋巴瘤的临床对比研究[J]. 中国肿瘤临床, 2011, 38(18): 1107-1110. [Zhang HL, Wang HQ, Fu K, et al. Comparative study of R-GemOx and RICE regimens as second-line treatments for refractory or relapsed DLBCL[J]. Chinese Journal of Clinical Oncology, 2011, 38(18): 1107-1110.] DOI: 10.3969/j.issn.1000-8179.2011.18.013.

16.Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study association trial[J]. Haematologica, 2013, 98(11): 1726-1731. DOI: 10.3324/haematol.2013.090597.

17.Rodríguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma[J]. Leuk Lymphoma, 2007, 48(11): 2172-2178. DOI: 10.1080/10428190701618268.

18.El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy[J]. Ann Oncol, 2007, 18(8):1363-1368. DOI: 10.1093/annonc/mdm133.

19.Ionescu-Ittu R, Shang A, Velde NV, et al. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world[J]. J Comp Eff Res, 2019, 8(13): 1067-1075. DOI: 10.2217/cer-2019-0062.

20.王潇潇, 黄慧强, 夏忠军, 等. 利妥昔单抗联合挽救化疗治疗复发或难治弥漫大B细胞性非霍奇金淋巴瘤的长期随访结果[J].南方医科大学学报, 2010, 30(4): 867-870, 874. [Wang XX. Huang HQ, Xia ZJ, et al. Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma[J]. Journal of Southern Medical University, 2010, 30(4): 867-870, 874.] DOI: 10.12122/j.issn.1673-4254.2010.04.058.

21.Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma[J]. Cancer Chemother Pharmacol, 2009, 64(5): 907-916. DOI: 10.1007/s00280-009-0941-9.

22.Sampol A, Rodriguez J, Galmés B, et al. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma[J]. Leuk Lymphoma, 2004, 45(6): 1289-1291. DOI: 10.1080/1042819032000159852.

23.中国临床肿瘤学会(CSCO)中国抗淋巴瘤联盟, 中国医师学会血液科医师分会. 中国淋巴瘤患者全程管理模式专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(5): 364-368. [Chinese Socirty of Clinical Oncology(CSCO) China Anti-lymphoma Alliance, Branch of Haematologist of Chinese Medical Association. Expert consensus on the whole-process management model of lymphoma patients in China (2021)[J]. Chinese Journal of Hematology, 2021, 42(5): 364-368.] DOI: 10.3760/cma.j.issn.0253-2727.2021.05.003.

24.孙燕. 2010 非霍奇金淋巴瘤临床实践指南(NCCN中国版）[EB/OL]. (2010)[2022-12-10]. http://www.elseviermed.cn/guide/detail/2011_breast_cancer_NCCN_guidelines_Chinese_version.

25.Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world's first oncology monoclonal antibody therapy[J]. Front Oncol, 2018, 8: 163. DOI: 10.3389/fonc.2018.00163.

26.Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine[J]. Ann Oncol, 2006, 17 Suppl 5: v7-v12. DOI: 10.1093/annonc/mdj941.

27.Rizzuto I, Ghazaly E, Peters GJ. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate[J]. Pharmacogenomics, 2017, 18(9): 911-925. DOI: 10.2217/pgs-2017-0034.

28.Zhu L, Li H, Du Q, at al. Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients[J]. Int J Clin Oncol, 2021, 26(12): 2194-2204. DOI: 10.1007/s10147-021-02034-3.

29.Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab  as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma[J]. Cancer Invest, 2006, 24(6): 593-600. DOI: 10.1080/07357900600814490.

30.Mey UJ, Olivieri A, Orlopp KS, et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for  patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis[J]. Leuk Lymphoma, 2006, 47(12): 2558-2566. DOI: 10.1080/10428190600926572.

31.Harting R, Venugopal P, Gregory SA, et al. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the  treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma[J]. Clin Lymphoma Myeloma, 2007, 7(6): 406-412. DOI: 10.3816/CLM.2007.n.019.

32.Fayad L, Ansell SM, Advani R, et al. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage  therapy for patients with diffuse large B-cell lymphoma relapsing after  rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a  randomized, double-blind, placebo-controlled phase 2b trial[J]. Leuk Lymphoma, 2015, 56(9) :2569-2578. DOI: 10.3109/10428194.2015.1007504.